​Although anthracyclines—chemotherapeutic agents that are extracted from Streptomyces bacterium—can be highly effective in the fight against various pediatric cancers, they carry a long-term risk of cardiovascular disease that continues to impact patients well into their adult lives. While this much is well known, the impact of specific anthracyclines on cardiac risk has not been adequately studied. In a study published in JAMA Oncology, researchers have now identified the relative long-ter...